Publications by authors named "Dominique Valla"

Article Synopsis
  • ACBP/DBI is a protein linked to metabolic-associated steatohepatitis and liver fibrosis, showing higher levels in affected patients, correlating strongly with NAFLD and FIB4 scores, regardless of age or body mass index.
  • A study used a monoclonal antibody to neutralize ACBP/DBI in various mouse models of liver disease, resulting in reduced signs of liver damage and halting disease progression.
  • The results suggest ACBP/DBI plays a causal role in liver conditions and could be a potential therapeutic target for treating liver diseases.
View Article and Find Full Text PDF

Portal vein thrombosis (PVT) refers to the development of a non-malignant obstruction of the portal vein, its branches, its radicles, or a combination. This Review first provides a comprehensive overview of all aspects of PVT, namely the specifics of the portal venous system, the risk factors for PVT, the pathophysiology of portal hypertension in PVT, the interest in non-invasive tests, as well as therapeutic approaches including the effect of treating risk factors for PVT or cause of cirrhosis, anticoagulation, portal vein recanalisation by interventional radiology, and prevention and management of variceal bleeding in patients with PVT. Specific issues are also addressed including portal cholangiopathy, mesenteric ischaemia and intestinal necrosis, quality of life, fertility, contraception and pregnancy, and PVT in children.

View Article and Find Full Text PDF
Article Synopsis
  • A study examined the risk of new thrombotic events in patients with non-cirrhotic portal vein thrombosis (NCPVT) linked to local factors after stopping anticoagulation therapy.
  • Out of 154 patients assessed, a significant portion had high-risk prothrombotic factors, with new thrombotic events occurring in 17 patients during a median follow-up of 52 months.
  • The results suggest that high-risk factors increase the likelihood of new thrombosis, while continuous anticoagulation treatment may reduce these risks effectively.
View Article and Find Full Text PDF

Background & Aims: Despite its high prevalence in the western world metabolic dysfunction-associated steatotic liver disease (MASLD) does not benefit from targeted pharmacological therapy. We measured healthcare utilisation and identified factors associated with high-cost MASLD patients in France.

Methods: The prevalent population with MASLD (including non-alcoholic steatohepatitis) in the CONSTANCES cohort, a nationally representative sample of 200,000 adults aged between 18 and 69, was linked to the French centralised national claims database (SNDS).

View Article and Find Full Text PDF
Article Synopsis
  • - This study conducts a meta-analysis to create a new grading system for liver steatosis using ultrasonography-based 2D-attenuation imaging (ATI), addressing the need for noninvasive tools in diagnosing liver disease.
  • - Eleven studies with 1374 patients revealed that ATI correlates strongly with histological and MRI-PDFF-confirmed steatosis, allowing for classification into four grades (S0 to S3) based on specific ATI measurements.
  • - The newly developed ATI grading system demonstrates high accuracy in determining liver steatosis, validated with independent patient cohorts and showing strong correlation with existing diagnostic methods.
View Article and Find Full Text PDF

Background & Aims: Non-invasive scores have been proposed to identify patients with fibrotic, metabolic dysfunction-associated steatohepatitis (MASH), who are at the highest risk of progression to complications of cirrhosis and may benefit from pharmacologic treatments. However, data in patients with type 2 diabetes (T2DM) are lacking. The aim of this multicenter prospective study was to perform a head-to-head comparison of FAST (FibroScan-aspartate aminotransferase [AST]), MAST (MRI-AST), MEFIB (magnetic resonance elastography [MRE] plus FIB-4), and FNI (fibrotic NASH index) for detecting fibrotic MASH in patients with T2DM.

View Article and Find Full Text PDF

Background & Aims: Similarly to the controlled attenuation parameter (CAP), the ultrasound-based attenuation imaging (ATI) can quantify hepatic steatosis. We prospectively compared the performance of ATI and CAP for the diagnosis of hepatic steatosis in patients with type 2 diabetes and nonalcoholic fatty liver disease using histology and magnetic resonance imaging-proton density fat fraction (MRI-PDFF) as references.

Methods: Patients underwent ATI and CAP measurement, MRI, and biopsy on the same day.

View Article and Find Full Text PDF

Background And Aim: Germline mutations of telomere-related genes (TRG) induce multiorgan dysfunction, and liver-specific manifestations have not been clearly outlined. We aimed to describe TRG mutations-associated liver diseases.

Approach And Results: Retrospective multicenter analysis of liver disease (transaminases > 30 IU/L and/or abnormal liver imaging) in patients with TRG mutations.

View Article and Find Full Text PDF
Article Synopsis
  • - This study investigates the potential of a new NRF2 activator, S217879, to treat metabolic-associated fatty liver disease (MAFLD) and fibrosis using a 3D model of patient-derived liver slices.
  • - After treating liver slices from MAFLD patients with S217879, researchers found no toxic effects and observed significant improvements in liver health, including reduced triglycerides, inflammation, and DNA damage compared to untreated samples.
  • - The results highlight that both S217879 and elafibranor, a standard treatment, effectively activate certain genes related to liver metabolism and antioxidant responses, with S217879 showing additional benefits in lowering inflammatory markers.
View Article and Find Full Text PDF

Background: No prospective diagnostic studies have directly compared widespread non-invasive liver tests in patients with type 2 diabetes (T2D) using the intention-to-diagnose method for each of the three main histological features of metabolic dysfunction associated steatotic liver disease - namely fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), and steatosis.

Aims: To compare the performance of nine tests using the intention-to-diagnose rather than the standard method, which would exclude non-evaluable participants METHODS: Biopsy was used as the reference with predetermined cut-offs, advanced fibrosis being the main endpoint. The Nash-FibroTest panel including FibroTest-T2D, SteatoTest-T2D and MashTest-T2D was optimised for type 2 diabetes.

View Article and Find Full Text PDF

Background: Nonalcoholic fatty liver disease (NAFLD) is increasing worldwide and is a growing cause of liver cirrhosis and cancer. The performance of the magnetic resonance elastography (MRE) visco-elastic parameters in diagnosing progressive forms of NAFLD, including nonalcoholic steatohepatitis (NASH) and substantial fibrosis (F ≥ 2), needs to be clarified.

Purpose: To assess the value of three-dimensional MRE visco-elastic parameters as markers of NASH and substantial fibrosis in mice with NAFLD.

View Article and Find Full Text PDF
Article Synopsis
  • A study aimed to identify undiagnosed patients with type 2 diabetes who also have nonalcoholic steatohepatitis (NASH) or advanced fibrosis (AF), highlighting the importance of early intervention.* -
  • The research involved screening 713 diabetic outpatients for liver disease, leading to 360 liver biopsies, which revealed high prevalence rates of NASH (58%) and AF (38%).* -
  • The study concluded that using readily available data effectively predicts liver complications in type 2 diabetes patients, emphasizing the need for further liver assessments.*
View Article and Find Full Text PDF

The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients.

View Article and Find Full Text PDF

BACKGROUND: In patients with noncirrhotic chronic portal vein thrombosis (PVT), the benefit of long-term anticoagulation is unknown. We assessed the effects of rivaroxaban on the risk of venous thromboembolism and portal hypertension-related bleeding in such patients. METHODS: In this multicenter, controlled trial, we randomly assigned patients with noncirrhotic chronic PVT without major risk factors for thrombosis to receive either rivaroxaban 15 mg/day or no anticoagulation.

View Article and Find Full Text PDF

Background: In magnetic resonance elastography (MRE), the precision of the observed mechanical depends on the ratio between mechanical wavelength and spatial resolution. Since the mechanical wavelength may vary with actuation frequency, between patients and depending on position, a unique spatial resolution may not always generate an optimal ratio for multifrequency acquisitions, in patients with varying degrees of disease or in mechanically heterogeneous organs.

Purpose: To describe an MRE reconstruction algorithm that adjusts the ratio between shear wavelength and pixel size, by locally resampling the matrix of shear displacement, and to assess its performance relative to existing reconstructions in different use cases.

View Article and Find Full Text PDF

Background & Aims: Liver sinusoidal obstruction syndrome (SOS) is a well-established complication of myeloablative conditioning regimens used in hematopoietic stem cell transplantation. Hepatic venous pressure gradient (HVPG) >10 mmHg was described as an accurate diagnostic tool for SOS in the 1990s. However, epidemiology and presentation of SOS have dramatically changed.

View Article and Find Full Text PDF
Article Synopsis
  • Liver biopsy carries a small risk of bleeding, but there are currently no reliable tools to predict this risk.
  • The study aimed to evaluate if global hemostasis tests or a clinical questionnaire could identify patients at higher risk for bleeding after liver biopsy, involving 302 patients.
  • Results indicated that none of the hemostasis tests or questionnaire items correlated with bleeding incidents, but increased pain 2 hours post-procedure may signal potential bleeding complications.
View Article and Find Full Text PDF

Alanine (ALT) and aspartate aminotransferases (AST) are intracellular enzymes involved in the metabolism of amino acids. The measurements of their activities are two of the most ordered tests in clinical laboratories, used to screen, diagnose and follow diseases affecting the liver. Recent works highlighted that reference values for ALT and AST vary according to the analytical method and the individual’s characteristics, like with many other biomarkers.

View Article and Find Full Text PDF

Background: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, which is associated with features of metabolic syndrome. NAFLD may progress in a subset of patients into nonalcoholic steatohepatitis (NASH) with liver injury resulting ultimately in cirrhosis and potentially hepatocellular carcinoma. Today, there is no approved treatment for NASH due to, at least in part, the lack of preclinical models recapitulating features of human disease.

View Article and Find Full Text PDF
Article Synopsis
  • In patients with non-alcoholic fatty liver disease (NAFLD), alpha-2 macroglobulin (A2M), apolipoprotein A1 (ApoA1), and haptoglobin levels are linked to liver fibrosis and inflammation, with specific trends observed in those with type 2 diabetes mellitus (T2DM).
  • The study analyzed data from three different cohorts to examine the effects of T2DM on these protein levels related to liver health before and during the COVID-19 pandemic.
  • Results showed that patients with NAFLD and T2DM showed greater increases in A2M and haptoglobin, along with a significant decrease in ApoA1, especially during the pandemic, indicating a heightened impact of T
View Article and Find Full Text PDF

Background & Aims: Recent non-malignant non-cirrhotic portal venous system thrombosis (PVT) is a rare condition. Among risk factors for PVT, cytomegalovirus (CMV) disease is usually listed based on a small number of reported cases. The aim of this study was to determine the characteristics and outcomes of PVT associated with CMV disease.

View Article and Find Full Text PDF
Article Synopsis
  • A recent study focused on predicting non-alcoholic liver disease in patients with type 2 diabetes using non-invasive blood tests for fibrosis, NASH, and steatosis.
  • The investigation involved 272 patients and assessed the performance of a new testing panel called Nash-FibroTest, which uses an Obuchowski measure for accuracy rather than traditional methods.
  • Results showed that the panel effectively diagnosed stages of fibrosis and grades of NASH and steatosis from a single blood sample, outperforming traditional assessment methods in some aspects.
View Article and Find Full Text PDF

Background: Eosinophilic gastroenteritis (EGE) is defined by the presence of gastrointestinal symptoms, with an abnormal eosinophilic infiltrate of the intestine wall and exclusion of other causes of secondary eosinophilia. EGE has three clinical presentations, depending on the depth of eosinophilic infiltration of the bowel wall. It individualizes into three types, namely mucosal, muscular, and subserosal.

View Article and Find Full Text PDF